Alcobra Ltd (ADHD) was Downgraded by WBB Securities to ” Sell” while Lowering the Price Target of the company shares to $ 4 from a previous price target of $5 . Earlier the firm had a rating of “Hold ” on the company shares. WBB Securities advised their investors in a research report released on Sep 12, 2016.
Many Wall Street Analysts have commented on Alcobra Ltd. Barclays Initiated Alcobra Ltd on Aug 1, 2016 to “Equal Weight”, Price Target of the shares are set at $8.Alcobra Ltd was Resumed by ROTH Capital to “Buy” on Jun 21, 2016.
Alcobra Ltd closed down -0.04 points or -0.83% at $4.8 with 72,485 shares getting traded on Wednesday. Post opening the session at $4.84, the shares hit an intraday low of $4.73 and an intraday high of $4.85 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug MG01CI to treat Attention Deficit Hyperactivity Disorder (ADHD) a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs higher divorce rates lower levels of socioeconomic attainment lower academic achievement unemployment and work place deficits increased risks for motor vehicle accidents greater likelihood of additional psychiatric disorders increased criminal activity and incarceration and higher rates of substance use and abuse. MG01CI product has completed phase two studies.